Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study

Risankizumab is a humanized monoclonal antibody that binds the p19 subunit of interleukin-23. It is approved for treatment of moderate-severe chronic plaque psoriasis. This retrospective study included 66 consecutive adults with moderate-to-severe psoriasis vulgaris treated with risankizumab in mono...

Full description

Bibliographic Details
Main Authors: Riccardo G. Borroni, Piergiorgio Malagoli, Luigi Gargiulo, Mario Valenti, Giulia Pavia, Paola Facheris, Emanuela Morenghi, Isotta Giunipero di Corteranzo, Alessandra Narcisi, Michela Ortoncelli, Paolo Dapavo, Antonio Costanzo
Format: Article
Language:English
Published: Medical Journals Sweden 2021-11-01
Series:Acta Dermato-Venereologica
Subjects:
risankizumab
psoriasis
real-life
Online Access:https://medicaljournalssweden.se/actadv/article/view/283

Internet

https://medicaljournalssweden.se/actadv/article/view/283

Similar Items